Your browser doesn't support javascript.
loading
The Impact of Intensive Versus Standard Anthelminthic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial.
Sanya, Richard E; Nkurunungi, Gyaviira; Hoek Spaans, Remy; Nampijja, Margaret; O'Hara, Geraldine; Kizindo, Robert; Oduru, Gloria; Kabuubi Nakawungu, Prossy; Niwagaba, Emmanuel; Abayo, Elson; Kabagenyi, Joyce; Zziwa, Christopher; Tumusiime, Josephine; Nakazibwe, Esther; Kaweesa, James; Muwonge Kakooza, Fred; Akello, Mirriam; Lubyayi, Lawrence; Verweij, Jaco; Nash, Stephen; van Ree, Ronald; Mpairwe, Harriet; Tukahebwa, Edridah; Webb, Emily L; Elliott, Alison M.
Afiliación
  • Sanya RE; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Nkurunungi G; Department of Internal Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Hoek Spaans R; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Nampijja M; Department of Clinical Research, London School of Hygiene and Tropical Medicine, United Kingdom.
  • O'Hara G; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Kizindo R; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Oduru G; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Kabuubi Nakawungu P; Department of Clinical Research, London School of Hygiene and Tropical Medicine, United Kingdom.
  • Niwagaba E; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Abayo E; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Kabagenyi J; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Zziwa C; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Tumusiime J; Entebbe Hospital, Wakiso District Local Government, Uganda.
  • Nakazibwe E; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Kaweesa J; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Muwonge Kakooza F; Entebbe Hospital, Wakiso District Local Government, Uganda.
  • Akello M; Entebbe Hospital, Wakiso District Local Government, Uganda.
  • Lubyayi L; Vector Control Division, Ministry of Health, Kampala, Uganda.
  • Verweij J; Koome Health Centre III, Mukono District Local Government, Uganda.
  • Nash S; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • van Ree R; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
  • Mpairwe H; Laboratory for Medical Microbiology and Immunology, St Elisabeth Hospital, Tilburg, The Netherlands.
  • Tukahebwa E; Medical Research Council Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom.
  • Webb EL; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Elliott AM; Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.
Clin Infect Dis ; 68(10): 1665-1674, 2019 05 02.
Article en En | MEDLINE | ID: mdl-30202872
ABSTRACT

BACKGROUND:

The prevalence of allergy-related diseases is increasing in low-income countries. Parasitic helminths, common in these settings, may be protective. We hypothesized that intensive, community-wide, anthelminthic mass drug administration (MDA) would increase allergy-related diseases, while reducing helminth-related morbidity.

METHODS:

In an open, cluster-randomized trial (ISRCTN47196031), we randomized 26 high-schistosomiasis-transmission fishing villages in Lake Victoria, Uganda, in a 11 ratio to receive community-wide intensive (quarterly single-dose praziquantel plus albendazole daily for 3 days) or standard (annual praziquantel plus 6 monthly single-dose albendazole) MDA. Primary outcomes were recent wheezing, skin prick test positivity (SPT), and allergen-specific immunoglobulin E (asIgE) after 3 years of intervention. Secondary outcomes included helminths, haemoglobin, and hepatosplenomegaly.

RESULTS:

The outcome survey comprised 3350 individuals. Intensive MDA had no effect on wheezing (risk ratio [RR] 1.11, 95% confidence interval [CI] 0.64-1.93), SPT (RR 1.10, 95% CI 0.85-1.42), or asIgE (RR 0.96, 95% CI 0.82-1.12). Intensive MDA reduced Schistosoma mansoni infection intensity the prevalence from Kato Katz examinations of single stool samples from each patient was 23% versus 39% (RR 0.70, 95% CI 0.55-0.88), but the urine circulating cathodic antigen test remained positive in 85% participants in both trial arms. Hookworm prevalence was 8% versus 11% (RR 0.55, 95% CI 0.31-1.00). There were no differences in anemia or hepatospenomegaly between trial arms.

CONCLUSIONS:

Despite reductions in S. mansoni intensity and hookworm prevalence, intensive MDA had no effect on atopy, allergy-related diseases, or helminth-related pathology. This could be due to sustained low-intensity infections; thus, a causal link between helminths and allergy outcomes cannot be discounted. Intensive community-based MDA has a limited impact in high-schistosomiasis-transmission fishing communities, in the absence of other interventions. CLINICAL TRIALS REGISTRATION ISRCTN47196031.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquistosomiasis / Hipersensibilidad / Antihelmínticos Tipo de estudio: Clinical_trials / Etiology_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquistosomiasis / Hipersensibilidad / Antihelmínticos Tipo de estudio: Clinical_trials / Etiology_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2019 Tipo del documento: Article